we believe conquering cancer is a big data problem. that’s why we built the world’s leading comprehensive liquid biopsy. this non-invasive tool for accessing and sequencing tumor dna is used by thousands of oncologists to help tens of thousands of advanced cancer patients. we believe the boom in cancer data acquisition we helped launch will drive important discoveries and new products. we’re working on some exciting ones, including in early detection, where the impact on patients can be profound. we’ve raised more than $500 million from investors including sequoia capital, khosla ventures, orbimed, and softbank.
Company profile
Ticker
GH
Exchange
Website
CEO
Helmy Eltoukhy
Employees
Incorporated
Location
Fiscal year end
Industry (SIC)
Quest Diagnostics • Labcorp • Fortrea • Radnet • Akumin • Burning Rock Biotech • Exact Sciences • Genomic Health • Invitae • Natera ...
SEC CIK
Corporate docs
Subsidiaries
Guardant Health AMEA, Inc. • Guardant Health Pte. Ltd. • Guardant Health Japan Corp. • Guardant Holdings (Switzerland) GmbH • Bellwether Bio, Inc. • Morpheus Merger Sub, Inc. • Guardant Health Screening Corp. • Guardant Health International, Inc. • Guardant Health UK Limited • Guardant Health Spain S.R.L. ...
IRS number
454139254
GH stock data
Latest filings (excl ownership)
8-K
Dr. Manuel Hidalgo Medina Joins Guardant Health Board of Directors
18 Jul 24
8-K
Submission of Matters to a Vote of Security Holders
14 Jun 24
8-K
Departure of Directors or Certain Officers
31 May 24
8-K
FDA Advisory Committee Panel Strongly Recommends Approval of Shield™ Blood Test
24 May 24
10-Q
2024 Q1
Quarterly report
9 May 24
8-K
Guardant Health Reports First Quarter 2024 Financial Results and Increases 2024 Revenue Guidance
9 May 24
ARS
2023 FY
Annual report to shareholders
25 Apr 24
DEFA14A
Additional proxy soliciting materials
25 Apr 24
DEF 14A
Definitive proxy
25 Apr 24
8-K
Departure of Directors or Certain Officers
22 Mar 24
Transcripts
GH
Earnings call transcript
2024 Q1
9 May 24
GH
Earnings call transcript
2023 Q4
22 Feb 24
GH
Earnings call transcript
2023 Q3
6 Nov 23
GH
Earnings call transcript
2023 Q2
3 Aug 23
GH
Earnings call transcript
2023 Q2
3 Aug 23
GH
Earnings call transcript
2023 Q1
9 May 23
GH
Earnings call transcript
2022 Q4
23 Feb 23
GH
Earnings call transcript
2022 Q3
4 Nov 22
GH
Earnings call transcript
2022 Q2
5 Aug 22
GH
Earnings call transcript
2022 Q1
6 May 22
Latest ownership filings
Financial summary
Quarter (USD) | Mar 24 | Dec 23 | Sep 23 | Jun 23 | |
---|---|---|---|---|---|
Revenue | |||||
Cost of revenue | |||||
Operating income | |||||
Operating margin | |||||
Net income | |||||
Net profit margin | |||||
Cash on hand | |||||
Change in cash | |||||
Diluted EPS |
Annual (USD) | Dec 23 | Dec 22 | Dec 21 | Dec 20 | |
---|---|---|---|---|---|
Revenue | |||||
Cost of revenue | |||||
Operating income | |||||
Operating margin | |||||
Net income | |||||
Net profit margin | |||||
Cash on hand | |||||
Change in cash | |||||
Diluted EPS |
Cash burn rate (est.) | Burn method: Change in cash | Burn method: Operating income | Burn method: FCF (opex + capex) | Last Q | Avg 4Q | Last Q | Avg 4Q | Last Q | Avg 4Q |
---|---|---|---|---|---|---|
Cash on hand (at last report) | 1.13 bn | 1.13 bn | 1.13 bn | 1.13 bn | 1.13 bn | 1.13 bn |
Cash burn (monthly) | 1.48 mm | (no burn) | 38.19 mm | 45.44 mm | 10.09 mm | 23.40 mm |
Cash used (since last report) | 5.71 mm | n/a | 147.67 mm | 175.68 mm | 39.03 mm | 90.48 mm |
Cash remaining | 1.12 bn | n/a | 981.59 mm | 953.58 mm | 1.09 bn | 1.04 bn |
Runway (months of cash) | 760.9 | n/a | 25.7 | 21.0 | 108.0 | 44.4 |
Institutional ownership, Q1 2024
93.1% owned by funds/institutions
13F holders | Current |
---|---|
Total holders | 246 |
Opened positions | 90 |
Closed positions | 70 |
Increased positions | 64 |
Reduced positions | 54 |
13F shares | Current |
---|---|
Total value | 2.16 tn |
Total shares | 113.99 mm |
Total puts | 1.62 mm |
Total calls | 2.48 mm |
Total put/call ratio | 0.7 |
Largest owners | Shares | Value |
---|---|---|
Vanguard | 11.44 mm | $235.93 bn |
BLK Blackrock | 11.01 mm | $227.22 bn |
Baillie Gifford & Co | 6.23 mm | $128.57 bn |
Deep Track Capital | 6.00 mm | $123.78 bn |
Cadian Capital Management | 5.79 mm | $119.51 bn |
Eventide Asset Managment | 4.18 mm | $86.22 bn |
Temasek | 4.11 mm | $84.81 bn |
Capital International Investors | 3.82 mm | $78.87 bn |
FMR | 3.03 mm | $62.44 bn |
PKW Parkwood | 2.80 mm | $1.90 mm |
Recent insider trades
Date | Owner | Security | Transaction | Code | Indirect | 10b5-1 | $Price | #Shares | $Value | #Remaining |
---|---|---|---|---|---|---|---|---|---|---|
17 Jul 24 | Medina Manuel Hidalgo | RSU Common Stock | Grant | Acquire A | No | No | 0 | 11,137 | 0.00 | 11,137 |
17 Jul 24 | Medina Manuel Hidalgo | Stock Option Common Stock | Grant | Acquire A | No | No | 32.55 | 17,029 | 554.29 k | 17,029 |
15 Jul 24 | Potter Myrtle S | Common Stock | Option exercise | Acquire M | No | No | 0 | 69 | 0.00 | 13,380 |
15 Jul 24 | Potter Myrtle S | RSU Common Stock | Option exercise | Dispose M | No | No | 0 | 69 | 0.00 | 1,026 |
15 Jul 24 | Musa Tariq | Common Stock | Option exercise | Acquire M | No | No | 0 | 250 | 0.00 | 3,997 |
15 Jul 24 | Musa Tariq | RSU Common Stock | Option exercise | Dispose M | No | No | 0 | 250 | 0.00 | 7,995 |
4 Jul 24 | Joyce Meghan V. | Common Stock | Option exercise | Acquire M | No | No | 0 | 66 | 0.00 | 10,279 |
4 Jul 24 | Joyce Meghan V. | RSU Common Stock | Option exercise | Dispose M | No | No | 0 | 66 | 0.00 | 863 |
News
Cathie Wood-Led Ark Invest Sells $8M In Tesla Shares Despite Bullish Autonomy Forecast
18 Jul 24
B of A Securities Maintains Buy on Guardant Health, Raises Price Target to $40
18 Jul 24
Assessing Guardant Health: Insights From 7 Financial Analysts
17 Jul 24
Goldman Sachs Maintains Buy on Guardant Health, Raises Price Target to $32
17 Jul 24
Canaccord Genuity Maintains Buy on Guardant Health, Raises Price Target to $38
4 Jun 24
Press releases
Guardant Health to Report Second Quarter 2024 Financial Results on August 7, 2024
24 Jul 24
Guardant Health Introduces Major Smart Liquid Biopsy Upgrade to Market-Leading Guardant360® Test, Further Extending Its Best-in-Class Performance
23 Jul 24
Dr. Manuel Hidalgo Medina Joins Guardant Health Board of Directors
18 Jul 24
Guardant Health introduces new Guardant360 TissueNext test with nearly 500 biomarkers to identify more treatment options for patients with advanced cancer
4 Jun 24
Guardant Health and Washington University to present study at 2024 ASCO meeting highlighting utility of ctDNA to address racial inequities in the use of targeted therapies and enrollment in clinical trials
3 Jun 24